JP2021177771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021177771A5 JP2021177771A5 JP2021118254A JP2021118254A JP2021177771A5 JP 2021177771 A5 JP2021177771 A5 JP 2021177771A5 JP 2021118254 A JP2021118254 A JP 2021118254A JP 2021118254 A JP2021118254 A JP 2021118254A JP 2021177771 A5 JP2021177771 A5 JP 2021177771A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- binding domain
- domain
- antigen binding
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000005809 anti-tumor immunity Effects 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000031146 intracellular signal transduction Effects 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819141P | 2013-05-03 | 2013-05-03 | |
| US61/819,141 | 2013-05-03 | ||
| US201361876492P | 2013-09-11 | 2013-09-11 | |
| US61/876,492 | 2013-09-11 | ||
| JP2019079616A JP2019146579A (ja) | 2013-05-03 | 2019-04-18 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019079616A Division JP2019146579A (ja) | 2013-05-03 | 2019-04-18 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021177771A JP2021177771A (ja) | 2021-11-18 |
| JP2021177771A5 true JP2021177771A5 (enExample) | 2022-03-24 |
| JP7221338B2 JP7221338B2 (ja) | 2023-02-13 |
Family
ID=51844005
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512083A Active JP6856188B2 (ja) | 2013-05-03 | 2014-05-02 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
| JP2019079616A Pending JP2019146579A (ja) | 2013-05-03 | 2019-04-18 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
| JP2021118254A Active JP7221338B2 (ja) | 2013-05-03 | 2021-07-16 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512083A Active JP6856188B2 (ja) | 2013-05-03 | 2014-05-02 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
| JP2019079616A Pending JP2019146579A (ja) | 2013-05-03 | 2019-04-18 | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10358494B2 (enExample) |
| EP (2) | EP2992020B1 (enExample) |
| JP (3) | JP6856188B2 (enExample) |
| KR (1) | KR102098985B1 (enExample) |
| CN (2) | CN105377897A (enExample) |
| AU (2) | AU2014259675B2 (enExample) |
| BR (1) | BR112015027567B1 (enExample) |
| DK (1) | DK2992020T3 (enExample) |
| ES (1) | ES2777940T3 (enExample) |
| HU (1) | HUE048312T2 (enExample) |
| IL (1) | IL242315B (enExample) |
| MX (1) | MX370173B (enExample) |
| PL (1) | PL2992020T3 (enExample) |
| PT (1) | PT2992020T (enExample) |
| WO (1) | WO2014179759A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2992020B1 (en) * | 2013-05-03 | 2020-01-15 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
| RU2727451C2 (ru) * | 2014-12-05 | 2020-07-21 | Сити Оф Хоуп | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 |
| HK1245140A1 (zh) * | 2014-12-31 | 2018-08-24 | Celgene Corporation | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
| JP6912386B2 (ja) * | 2015-01-26 | 2021-08-04 | ザ ユニバーシティー オブ シカゴ | 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞 |
| CN107683289B (zh) | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
| ES3007649T3 (en) * | 2015-01-29 | 2025-03-20 | Univ Minnesota | Chimeric antigen receptors, compositions, and methods |
| EP3258967A4 (en) | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| WO2016164370A1 (en) * | 2015-04-06 | 2016-10-13 | Ohio State Innovation Foundation | Egfr-directed car therapy for glioblastoma |
| EP3298046B1 (en) * | 2015-05-20 | 2025-02-12 | Cellectis | Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy |
| EP4424326A3 (en) * | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| EP3339320A4 (en) | 2015-08-17 | 2019-01-23 | Seoul National University R&DB Foundation | CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF |
| US11517590B2 (en) * | 2015-10-08 | 2022-12-06 | National University Corporation Tokai National Higher Education And Research System | Method for preparing genetically-modified T cells which express chimeric antigen receptor |
| TW201740958A (zh) * | 2016-01-15 | 2017-12-01 | 依圖比克斯公司 | 用於t細胞免疫療法之方法及組合物 |
| WO2017130223A2 (en) | 2016-01-29 | 2017-08-03 | Virocan Therapeutics Pvt. Ltd. | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| US11365237B2 (en) | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| EP3445407B1 (en) * | 2016-04-22 | 2022-12-14 | CRAGE medical Co., Limited | Compositions and methods of cellular immunotherapy |
| CN109844099B (zh) | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
| CN106279432B (zh) * | 2016-08-10 | 2019-09-20 | 深圳市再生之城生物医药技术有限公司 | 一种vc-car分子及在清除hiv-1感染细胞中的应用 |
| CN108699163B (zh) * | 2016-09-28 | 2021-11-19 | 阿思科力(苏州)生物科技有限公司 | 一种多基因重组嵌合抗原受体分子及其应用 |
| BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics Inc | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
| JP7033601B2 (ja) * | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
| US11744862B2 (en) * | 2017-03-20 | 2023-09-05 | City Of Hope | CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis |
| AU2018243920B2 (en) * | 2017-03-28 | 2024-12-12 | Mayo Foundation For Medical Education And Research | Human PD1 peptide vaccines and uses thereof |
| WO2018189360A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| EP3648799A4 (en) * | 2017-07-07 | 2021-06-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with mutated cd28 costimulatory domains |
| US11639508B2 (en) | 2017-07-14 | 2023-05-02 | The Johns Hopkins University | Engineered TSC2 |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| KR20200063215A (ko) * | 2017-10-06 | 2020-06-04 | 오슬로 유니버시테시케후스 에이치에프 | 키메라 항원 수용체 |
| US12077598B2 (en) | 2018-03-16 | 2024-09-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with mutated CD28 phosphorylation sites |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3806871A4 (en) | 2018-06-12 | 2022-02-23 | The Regents of the University of California | SINGLE-CHAIN BISPECIFIC CHEMICAL ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER |
| WO2020009868A1 (en) * | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| EP3818148A4 (en) * | 2018-07-05 | 2022-09-28 | Emory University | TRANSDUCTION OF CONGENITAL IMMUNE COMPETENT CELLS USING AAV6 |
| WO2020025039A1 (zh) * | 2018-08-03 | 2020-02-06 | 南京驯鹿医疗技术有限公司 | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| CN113966397A (zh) | 2019-03-08 | 2022-01-21 | 黑曜石疗法公司 | 人碳酸酐酶2组合物和用于可调调节的方法 |
| IL316764A (en) | 2019-04-03 | 2025-01-01 | Prec Biosciences Inc | Genetically modified immune cells containing shRNA-targeted microRNA (shRNAmir) |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CA3140668A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| KR20220038362A (ko) | 2019-07-02 | 2022-03-28 | 프레드 헛친슨 켄서 리서치 센터 | 재조합 ad35 벡터 및 관련 유전자 요법 개선 |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| AR120430A1 (es) * | 2019-11-08 | 2022-02-16 | Humanigen Inc | Células car-t dirigidas a epha3 para el tratamiento de tumores |
| WO2022002919A1 (en) * | 2020-06-29 | 2022-01-06 | Julius-Maximilians-Universität Würzburg | Slamf7 cars |
| WO2022031602A1 (en) * | 2020-08-06 | 2022-02-10 | Promab Biotechnologies, Inc. | Cs1- antibody and anti-cs1-car-t cells |
| WO2022063302A1 (zh) * | 2020-09-25 | 2022-03-31 | 克莱格医学有限公司 | 免疫细胞活性调节 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| CN120344563A (zh) * | 2022-12-02 | 2025-07-18 | 广州荔泰生物科技有限公司 | 人cs1 car-t细胞 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| WO2010017103A2 (en) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| EP2361263A1 (en) | 2008-10-31 | 2011-08-31 | Abbott Biotherapeutics Corp. | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
| ES2754394T3 (es) * | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| BR112013012138B1 (pt) * | 2010-11-22 | 2022-02-22 | Innate Pharma Sa | Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir) |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101956751B1 (ko) * | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
| US20140314667A1 (en) | 2011-11-16 | 2014-10-23 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant viii related disorders |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CN104968788A (zh) | 2012-12-07 | 2015-10-07 | 索拉兹米公司 | 包括原始小球藻脂质途径基因的基因工程化微生物菌株 |
| CN103224561A (zh) | 2013-01-16 | 2013-07-31 | 天津大学 | 葡萄球菌肠毒素小分子抗体及制备方法及用途 |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP2992020B1 (en) * | 2013-05-03 | 2020-01-15 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| CN105829349B (zh) | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| US20210087275A1 (en) * | 2018-03-16 | 2021-03-25 | Cytoimmune Therapeutics, Inc. | Bispecific antibody car cell immunotherapy |
-
2014
- 2014-05-02 EP EP14791494.9A patent/EP2992020B1/en active Active
- 2014-05-02 DK DK14791494.9T patent/DK2992020T3/da active
- 2014-05-02 CN CN201480030178.9A patent/CN105377897A/zh active Pending
- 2014-05-02 PL PL14791494T patent/PL2992020T3/pl unknown
- 2014-05-02 HU HUE14791494A patent/HUE048312T2/hu unknown
- 2014-05-02 ES ES14791494T patent/ES2777940T3/es active Active
- 2014-05-02 JP JP2016512083A patent/JP6856188B2/ja active Active
- 2014-05-02 PT PT147914949T patent/PT2992020T/pt unknown
- 2014-05-02 MX MX2015015182A patent/MX370173B/es active IP Right Grant
- 2014-05-02 KR KR1020157033493A patent/KR102098985B1/ko active Active
- 2014-05-02 WO PCT/US2014/036684 patent/WO2014179759A1/en not_active Ceased
- 2014-05-02 CN CN202210255676.XA patent/CN115028735A/zh active Pending
- 2014-05-02 BR BR112015027567-2A patent/BR112015027567B1/pt active IP Right Grant
- 2014-05-02 US US14/888,877 patent/US10358494B2/en active Active
- 2014-05-02 AU AU2014259675A patent/AU2014259675B2/en active Active
- 2014-05-02 EP EP20150396.8A patent/EP3663320A1/en not_active Withdrawn
-
2015
- 2015-10-28 IL IL242315A patent/IL242315B/en active IP Right Grant
-
2017
- 2017-05-17 US US15/597,436 patent/US10227409B2/en active Active
-
2019
- 2019-04-18 JP JP2019079616A patent/JP2019146579A/ja active Pending
- 2019-05-31 AU AU2019203823A patent/AU2019203823B2/en active Active
- 2019-07-09 US US16/506,327 patent/US11845794B2/en active Active
-
2021
- 2021-07-16 JP JP2021118254A patent/JP7221338B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021177771A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2021087455A5 (enExample) | ||
| JP2021094037A5 (enExample) | ||
| JP2020511136A5 (enExample) | ||
| JP2022113880A5 (enExample) | ||
| JP2022109953A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| JP2023059873A5 (enExample) | ||
| JP2021106605A5 (enExample) | ||
| JP2023071729A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| JP2023139070A5 (enExample) | ||
| JP2020513754A5 (enExample) | ||
| JP2018504459A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2020533958A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2016520074A5 (enExample) | ||
| JP2018504143A5 (enExample) | ||
| JPWO2020228825A5 (enExample) | ||
| JPWO2020228824A5 (enExample) |